Targeted epigenetic therapy in inflammatory bowel disease

A.M.I.M. Elfiky

Targeted epigenetic therapy in inflammatory bowel disease

Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

Abstract

Current inflammatory bowel disease (IBD) treatments have high rates of non‐responsiveness, necessitating more specific and safer options to be introduced. This dissertation addresses the potential of epigenetic medicines in IBD. The first wave of epigenetic drugs lack specificity and have wide range of toxicities that limit clinical translation of their potent anti-inflammatory

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Amsterdam
Supervisors/Advisors	de Jonge, Wouter, Supervisor Bell, Matthew J., Supervisor, External person Heinsbroek, Sigrid, Supervisor
Award date	13 Oct 2023
Print ISBNs	9789493353190
Publication status	Published - 2023

Access to Document

Cite this

@phdthesis{5d9ba48791f844eca887c0385e68e5db,

title = "Targeted epigenetic therapy in inflammatory bowel disease",

abstract = "Current inflammatory bowel disease (IBD) treatments have high rates of non‐responsiveness, necessitating more specific and safer options to be introduced. This dissertation addresses the potential of epigenetic medicines in IBD. The first wave of epigenetic drugs lack specificity and have wide range of toxicities that limit clinical translation of their potent anti-inflammatory",

author = "A.M.I.M. Elfiky",

year = "2023",

language = "English",

isbn = "9789493353190",

type = "Phd-Thesis - Research and graduation internal",

school = "University of Amsterdam",

}

TY - THES

T1 - Targeted epigenetic therapy in inflammatory bowel disease

AU - Elfiky, A.M.I.M.

PY - 2023

Y1 - 2023

N2 - Current inflammatory bowel disease (IBD) treatments have high rates of non‐responsiveness, necessitating more specific and safer options to be introduced. This dissertation addresses the potential of epigenetic medicines in IBD. The first wave of epigenetic drugs lack specificity and have wide range of toxicities that limit clinical translation of their potent anti-inflammatory

AB - Current inflammatory bowel disease (IBD) treatments have high rates of non‐responsiveness, necessitating more specific and safer options to be introduced. This dissertation addresses the potential of epigenetic medicines in IBD. The first wave of epigenetic drugs lack specificity and have wide range of toxicities that limit clinical translation of their potent anti-inflammatory

UR - https://pure.uva.nl/ws/files/139717190/Licence_Agreement_co_signed_.pdf

M3 - Phd-Thesis - Research and graduation internal

SN - 9789493353190

ER -

Targeted epigenetic therapy in inflammatory bowel disease

Abstract

Access to Document

Other files and links

Cite this